Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANG Lifesciences IndiaBOM:540694 +3.47%63 Days Payable is 354.49 as of Mar. 2026, which is 129% above its 10-year median of 155.04. GuruFocus rates BOM:540694 with a GF Score™ of 63/100 and a GF Value™ of ₹30.63 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, ANG Lifesciences India ranks better than 92.77% on this metric.
The historical rank and industry rank for ANG Lifesciences India's Days Payable or its related term are showing as below:
BOM:540694'
s Days Payable Range Over the Past 10 Years
Min: 88.19 Med: 155.04 Max: 404.81
Current: 389.71
During the past 13 years, ANG Lifesciences India's highest Days Payable was 404.81. The lowest was 88.19. And the median was 155.04.
BOM:540694's Days Payable is ranked better than 92.77% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:540694: 389.71
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANG Lifesciences India's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANG Lifesciences India Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANG Lifesciences India's Days Payable distribution charts can be found below:
* The bar in red indicates where ANG Lifesciences India's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ANG Lifesciences India's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANG Lifesciences India (BOM:540694) has a Days Payable of 354.49 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ANG Lifesciences India and its competitors. This is 129% above median its historical median of 155.04. Over the past decade, ANG Lifesciences India's Days Payable has ranged from 88.19 to 404.81. According to the industry distribution chart, ANG Lifesciences India ranks #67 out of 927 companies in the Drug Manufacturers industry, placing it in the top 7.2%.
Is ANG Lifesciences India's Days Payable too high?
ANG Lifesciences India's current Days Payable of 354.49 is 129% above median its 10-year median of 155.04. Over the past 10 years, this metric has ranged from a low of 88.19 to a high of 404.81. The Drug Manufacturers industry median Days Payable is 90.38. ANG Lifesciences India's value of 354.49 is 292.2% above this industry median. Based on the distribution chart, ANG Lifesciences India ranks #67 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ANG Lifesciences India has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ANG Lifesciences India ranks #67 out of 927 companies for Days Payable. This places ANG Lifesciences India in the top 7% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. ANG Lifesciences India's value of 354.49 is 292.2% above this benchmark. Historically, ANG Lifesciences India's own Days Payable has ranged from 88.19 to 404.81 over the past decade. While the company's 10-year median is 155.04 vs. the industry median of 90.38, ANG Lifesciences India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANG Lifesciences India's current Days Payable of 354.49 is 292.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ANG Lifesciences India and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANG Lifesciences India's current Days Payable is 354.49, which is 129% above median its own 10-year median of 155.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹30.63, compared to a current price of ₹34.01 — trading 11% above its estimated fair value. The current Days Payable is 354.49, which is 129% above median its 10-year median of 155.04 and 292.2% above the Drug Manufacturers industry median of 90.38. ANG Lifesciences India's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current Days Payable is 354.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued.
The current stock price of ₹34.01 is trading 11% above its estimated GF Value™ of ₹30.63.
GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.
Key valuation signals for BOM:540694:
Days Payable: 354.49 (129% above median its 10-year median of 155.04)
GF Value™: ₹30.63 vs. price of ₹34.01 (11% above fair value)
Industry Position: 292.2% above the Drug Manufacturers median (#67 of 927)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
63GF Score
Get the complete analysis for BOM:540694
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
